Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Canadian Journal of Physiology and Pharmacology

• Publication date

  1997-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1139/Y97-130PMID 9365818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NSAID-Induced Gastrointestinal Damage

  2012cited by this paper
• The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound

  2005cited by this paper
• New insights into the mode of action of anti-inflammatory drugs

  2005cited by this paper
• Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells

  1997cited by this paper
• Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

  1997cited by this paper
• Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

  1996cited by this paper
• Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts.

  1996cited by this paper
• Inhibition of lymphocyte adhesion to cytokine-activated synovial fibroblasts by glucocorticoids involves the attenuation of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 gene expression.

  1996cited by this paper
• Prostaglandin synthase 2.

  1996cited by this paper
• Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection.

  1996cited by this paper
• Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence.

  1996cited by this paper
• Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.

  1996cited by this paper
• Cyclooxygenase-2 and its regulation in inflammation

  1996cited by this paper
• Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam Study.

  1996cited by this paper
• Tenidap, a structurally novel drug for the treatment of arthritis: Antiinflammatory and analgesic properties

  1996cited by this paper
• Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.

  1996cited by this paper
• Constitutive cyclooxygenase (COX‐1) and inducible cyclooxygenase (COX‐2): Rationale for selective inhibition and progress to date

  1996cited by this paper
• Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms.

  1995cited by this paper
• NSAIDs, Cox-2 inhibitors, and the gut.

  1995cited by this paper
• Mannose-binding protein genotypes and recurrent infection.

  1995cited by this paper
• Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance

  1995cited by this paper
• NSAIDs, Cox-2 inhibitors, and the gut.

  1995cited by this paper
• Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

  1995cited by this paper
• Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors

  1995cited by this paper
• Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 and Cox-1 inhibitors

  1995cited by this paper
• NSAIDs, Cox-2 inhibitors, and the gut.

  1995cited by this paper
• Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.

  1995cited by this paper
• NSAIDs, Cox-2 inhibitors, and the gut

  1995cited by this paper
• T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts.

  1995cited by this paper
• SELECTIVE CYCLOOXYGENASE INHIBITORS : NOVEL 4-SPIRO 1,2-DIARYLCYCLOPENTENES ARE POTENT AND ORALLY ACTIVE COX-2 INHIBITORS

  1995cited by this paper
• GASTRODUODENAL TOXICITY OF DIFFERENT NONSTEROIDAL ANTIINFLAMMATORY DRUGS

  1995cited by this paper
• Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.

  1995cited by this paper
• NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

  1994cited by this paper
• Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.

  1994cited by this paper
• The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage--potential for development of gastrointestinal tract safe NSAIDs.

  1994cited by this paper
• Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.

  1994cited by this paper
• Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.

  1994cited by this paper
• Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.

  1994cited by this paper
• Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs.

  1994cited by this paper
• Selective inhibition of cyclooxygenase 2.

  1994cited by this paper
• Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.

  1994cited by this paper
• Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

  1994cited by this paper
• Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

  1994cited by this paper
• Mechanisms of gastric and duodenal damage and protection.

  1992cited by this paper
• Limited utilization of exogenous arachidonic acid by the prostaglandin cyclooxygenase in gastric mucosa: the role of protein binding, glutathione peroxidase, and hydrogen peroxides.

  1992cited by this paper
• Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.

  1992cited by this paper
• The unique pharmacologic profile of nabumetone.

  1992cited by this paper
• Mechanisms of NSAID-induced ulcerogenesis: structural properties of drugs, focus on the microvascular factors, and novel approaches for gastro-intestinal protection.

  1992cited by this paper
• A new test for evaluating nonsteroidal anti-inflammatory drugs in vitro: inhibition of prostaglandin E2 production in minced intestinal tissue.

  1992cited by this paper
• Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding.

  1991cited by this paper
• Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.

  1990cited by this paper
• In vivo assessment of precursor induced prostaglandin release within the rat gastric lumen.

  1989cited by this paper
• Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti‐inflammatory agents

  1983cited by this paper

• Latest developments in small molecule analgesics: heterocyclic scaffolds II.

  2025cites this paper
• In vitro and in silico neuroprotective evaluation of new biotransformation metabolites of (-)-α-bisabolol

  2025cites this paper
• Predicting therapeutic and side effects from drug binding affinities to human proteome structures

  2024cites this paper
• De novo generation of dual-target compounds using artificial intelligence

  2024cites this paper
• Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health

  2023cites this paper
• Shared and Related Molecular Targets and Actions of Salicylic Acid in Plants and Humans

  2023cites this paper
• Microbial Transformation of the Sesquiterpene Lactone, Vulgarin, by Aspergillus niger

  2023cites this paper
• Evaluation of Anti-inflammatory Activity of Novel HDAC Inhibitors using in vitro Methods

  2022cites this paper
• Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery.

  2021cites this paper
• Characterization of human sulfotransferases catalyzing the formation of p-cresol sulfate and identification of mefenamic acid as a potent metabolism inhibitor and potential therapeutic agent for detoxification.

  2021cites this paper
• Neuroimmunological complications arising from chemotherapy‐induced gut toxicity and opioid exposure in female dark agouti rats

  2021cites this paper
• Identification and HPLC Purification of Aspirin (Acetylsalicylic Acid) from the Seed Coats, Leaves and Bark of Givotia Rottleriformis Griff.

  2021cites this paper
• Identification of an irreversible PPARγ antagonist with potent anticancer activity

  2020cites this paper
• Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer

  2020cites this paper
• Brain-immune crosstalk in the treatment of major depressive disorder.

  2020cites this paper
• Different impacts of various tocolytic agents on increased risk of postoperative hemorrhage in preterm labor women undergoing Cesarean delivery

  2020cites this paper
• Sila-Ibuprofen.

  2020cites this paper
• From the Bottom Up: Chemotherapy-Induced Gut Toxicity, Glial Reactivity and Cognitive Impairment

  2019cites this paper
• Validation of a Sensitive L C / MS / MS Method for the Determination of Imrecoxib and its Two Metabolites in Human Plasma : Application to a Pharmacokinetic Study

  2018cites this paper
• Efecto tóxico del ibuprofeno y meloxicam en la estructura histológica de testículos y calidad seminal de ratas albinas (Rattus norvegicus) variedad Sprague Dawley

  2018cites this paper
• Practical approaches to adverse outcome pathway development and weight‐of‐evidence evaluation as illustrated by ecotoxicological case studies

  2017cites this paper
• Non-Steroidal Anti-Inflammatory Drugs in Cyclooxygenases 1 and 2 : Binding modes and mechanisms from computational methods and free energy calculations

  2017cites this paper
• Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal

  2017cites this paper
• Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH‐naproxen (AVT‐219) a dual NO‐ and H2S‐releasing hybrid

  2016cites this paper
• Recent Advances in Anti-inflammatory Potential of Pyridazinone Derivatives.

  2016cites this paper
• Differential Effectiveness of Clinically-Relevant Analgesics in a Rat Model of Chemotherapy-Induced Mucositis

  2016cites this paper
• Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer

  2016influential citation
• Celecoxib is an inhibitor of enzyme acetylcholinesterase.

  2016cites this paper
• NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties

  2015cites this paper
• Origin of the Enigmatic Stepwise Tight-Binding Inhibition of Cyclooxygenase-1.

  2015cites this paper
• Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling☆

  2015cites this paper
• Marginally Designed New Profen Analogues Have the Potential to Inhibit Cyclooxygenase Enzymes

  2015cites this paper
• Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes

  2014cites this paper
• Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.

  2014cites this paper
• Study of Anthranylic Acid Derivatives: Mefenamic Acid and Its Various Analogues

  2014influential citation
• Investigation of STW 5 (Iberogast®) preventive effects in experimental sepsis

  2013cites this paper
• Inflammation in Retinal Disease

  2013cites this paper
• Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease

  2013cites this paper
• COX-2 inhibition: what we learned--a controversial update on safety data.

  2013cites this paper
• Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

  2013cites this paper
• Etodolac, A Preferential COX-2 Inhibitor, Does Not Inhibit Platelet Aggregation in A Randomized Placebo-controlled Trial

  2013cites this paper
• Cyclooxygenase‐2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine‐induced presynaptic enhancement at the vertebrate neuromuscular junction

  2013influential citation
• Noni Seed Oil Topical Safety, Efficacy, and Potential Mechanisms of Action *

  2012cites this paper
• NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.

  2012cites this paper
• Sunburn (fohia) Healing Effects of Noni: Is it a Mechanism Involving Its Inhibitory Effects on MMP, COX-2 and Cat-G Enzymes?

  2012influential citation
• Bioactive sulfoximines: syntheses and properties of Vioxx analogs.

  2011cites this paper
• Comparative evaluation of local infiltration of articaine, articaine plus ketorolac, and dexamethasone on anesthetic efficacy of inferior alveolar nerve block with lidocaine in patients with irreversible pulpitis.

  2011cites this paper
• Inhibition of hematopoietic prostaglandin D synthase improves allergic nasal blockage in guinea pigs.

  2011cites this paper
• Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase.

  2011cites this paper
• Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs

  2010cites this paper
• NSAID Action and the Foundations for Cardiovascular Toxicity

  2010cites this paper
• Estrogenic and progestagenic effects of extracts of Justicia pectoralis Jacq., an herbal medicine from Costa Rica used for the treatment of menopause and PMS.

  2010cites this paper
• Use of transgenic mice as models for prostate cancer chemoprevention.

  2010cites this paper
• European perspectives on upcoming analgesics: What do they have that we don't—and what do they think about them?

  2010cites this paper
• Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal

  2010cites this paper
• On the biological activity of drug molecules: Busulfan and nabumetone

  2010cites this paper
• Nonsteroidal anti-inflammatory drugs in ophthalmology.

  2010cites this paper
• Comparative evaluation of effect of preoperative oral medication of ibuprofen and ketorolac on anesthetic efficacy of inferior alveolar nerve block with lidocaine in patients with irreversible pulpitis: a prospective, double-blind, randomized clinical trial.

  2010cites this paper
• The COXIB experience: a look in the rearview mirror.

  2009cites this paper
• Analgesic and Antipyretic Activities of a Novel Tetrapeptide in Rats

  2009cites this paper
• Immunopharmacology and clinical safety and efficacy of iguratimod, a novel anti-rheumatic drug

  2009cites this paper
• Studies on the pathogenesis and management of prostate carcinoma in dogs

  2009cites this paper
• Asian Journal of Pharmacodynamics and Pharmacokinetics

  2009cites this paper
• In vitro analysis of inflammatory responses following environmental exposure to pharmaceuticals and inland waters.

  2009cites this paper
• Iguratimod (T-614): A novel disease modifying anti-rheumatic drug

  2009influential citation
• A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity

  2009cites this paper
• Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells.

  2009cites this paper
• Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-α converting enzyme, calpain and kinases

  2009influential citation
• Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.

  2008cites this paper
• NEUROPLASTICITY OF MICTURITION REFLEX PATHWAYS WITH CYCLOPHOSPHAMIDE-INDUCED CYSTITIS

  2008cites this paper
• Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation.

  2008cites this paper
• Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

  2008cites this paper
• Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697).

  2007cites this paper
• Inibizione della ciclossigenasi e rischio cardiovascolare: farmaci antinfiammatori non steroidei tradizionali e selettivi per la ciclossigenasi-2 Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

  2007cites this paper
• Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti.

  2007cites this paper
• Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge.

  2007cites this paper
• Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.

  2007cites this paper
• Acetaminophen, Phenacetin and Dipyrone Do Not Modulate Pressor Responses to Arachidonic Acid or to Pressor Agents

  2007cites this paper
• Molecular docking study of the affinity of CYP2C9 and CYP2D6 for imrecoxib

  2007cites this paper
• COX-2 inhibitors and cardiovascular risk.

  2007influential citation
• Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.

  2007cites this paper
• Cyclooxygenase-2 mediates the sensitizing effects of systemic IL-1-beta on excitotoxic brain lesions in newborn mice.

  2007cites this paper
• Metabolism and excretion of imrecoxib in rat

  2006influential citation
• Enhanced Plasma Concentration by Selective Deuteration of Rofecoxib in Rats

  2006cites this paper
• New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases

  2006cites this paper
• Nimesulide inhibits lipopolysaccharide-induced production of superoxide anions and nitric oxide and iNOS expression in alveolar macrophages.

  2006cites this paper
• Preadministration of High-Dose Salicylates, Suppressors of NF-κB Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy

  2006cites this paper
• Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib

  2006cites this paper
• Partial prostatectomy using Nd:YAG laser for management of canine prostate carcinoma.

  2006cites this paper
• Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells

  2006cites this paper
• Metabolism and excretion of imrecoxib in rat.

  2006cites this paper
• LES RÉACTIONS ALLERGIQUES ET PSEUDO-ALLERGIQUES AUX ANTALGIQUES, ANTI-PYRÉTIQUES ET ANTI-INFLAMMATOIRES NON STÉROÏDIENS

  2006cites this paper
• Analgésicos antipiréticos: Aspectos básicos

  2006cites this paper
• INHIBITORS OF CYCLO-OXYGENASE-2 AND SECRETORY PHOSPHOLIPASE A 2 (GROUP IIa) PRESERVE BONE ARCHITECTURE FOLLOWING OVARIECTOMY IN ADULT RATS

  2006cites this paper
• Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats.

  2006cites this paper
• PHARMACOKINETICS OF DICLOFENAC IN PIGS AFTER INTRAMUSCULAR ADMINISTRATION OF A SINGLE DOSE

  2006cites this paper
• COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

  2006cites this paper
• Antipyretic analgesics: basic aspects

  2006cites this paper
• Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT1A1,1A3 and 1A8

  2006cites this paper
• Mechanism of Action of Paracetamol

  2005cites this paper